GlassScriptPhysician profile
Mary Benard
NPI 1962861864
$2,187.84
in general payments reported to CMS, 2019-2025
24 companies · $850 in 2025
The $850 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $297 · 2022: $179 · 2023: $143 · 2024: $719 · 2025: $850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,712.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $576.16 | 2021-2024 | Proclaim |
| Astrazeneca Pharmaceuticals LP | $258.43 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $189.35 | 2023-2025 | |
| Novo Nordisk INC | $159.44 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lundbeck LLC | $113.35 | 2024-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.02 | 2024-2025 | Jardiance |
| Agios Pharmaceuticals, INC. | $94.54 | 2023-2024 | Pyrukynd |
| Abbvie INC. | $91.35 | 2024-2025 | |
| Glaxosmithkline, LLC. | $89.04 | 2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $80.58 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $76.13 | 2025 | Voquezna |
| Lilly USA, LLC | $52.25 | 2025 | Jardiance, Zepbound, Mounjaro |
| Amgen INC. | $51.80 | 2024-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $39.28 | 2024 | Spravato |
| Esperion Therapeutics, INC. | $32.02 | 2024-2025 | Nexletol |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $30.93 | 2022 | |
| Dexcom, INC. | $30.91 | 2024-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.59 | 2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $19.37 | 2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $19.11 | 2024 | |
| Xeris Pharmaceuticals, INC. | $18.48 | 2024 | Keveyis |
| Exact Sciences Corporation | $16.23 | 2025 | Cologuard Collection Kit |
| Antares Pharma, INC. | $15.33 | 2024 | Xyosted |
| Kowa Pharmaceuticals America, INC. | $15.15 | 2024 | Livalo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Benard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.